openPR Logo
Press release

KOIS Invest designs the world’s first Humanitarian Impact Bond for the International Committee of the Red Cross

09-13-2017 11:50 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Kois Invest

ThE humanitarian impact bond has secured private funding for rehabilitation centres for people with physical disabilities.

ThE humanitarian impact bond has secured private funding for rehabilitation centres for people with physical disabilities.

Brussels, 11 September, 2017 -- The world’s first humanitarian impact bond (HIB), issued by the International Committee of the Red Cross (ICRC) and designed by KOIS Invest, was publicly announced on September 6, 2017. The Programme for Humanitarian Impact Investment (PHII) has secured private funding to build rehabilitation centres supporting people with physical disabilities in three post-conflict countries in Africa. It is the first application of an impact bond mechanism to the humanitarian space and to the underserved field of physical rehabilitation. This is a landmark transaction that will hopefully drive further private sector investments towards underfunded humanitarian and developmental issues. As one of the largest Impact bonds ever launched, it is also the first multi-country operations impact bond, and the first one to unite several European countries as outcome funders.

The CHF 26 million (USD 27 million) financial instrument will make funds available for the construction of three innovative physical rehabilitation centres in the Democratic Republic of Congo, Mali and Nigeria, the training of local physical rehabilitation staff, as well as for the first two years of operations of the centres. The structure is based on a “pay-for-success” mechanism where (i) investors (Munich Re and clients of Lombard Odier) provide upfront capital to finance the programme, and (ii) outcome funders (the governments of Belgium, Switzerland, Italy and the UK, as well as La Caixa Foundation) will pay back investors with a financial return (up to 7%) if the programme outperforms pre-agreed objectives. The success rate will be measured according to the number of people having (re)gained mobility per local rehabilitation professional working in the centres at the end of the impact bond’s five-year lifespan. The PHII allows for donors and investors to do what they respectively do best: donors pay for what they value - i.e., outcomes - and investors bear risks and price them accordingly, while lending to a humanitarian programme.

“For many years now the ICRC has been looking for new funding from governments that do not yet provide support to the ICRC, private sources, and innovative funding arrangements. This is an important learning experience for us. If it works, it will be a stepping stone to larger projects”, said Tobias Epprecht, Senior Manager at the ICRC.

“The challenge was to develop a product that would make investors comfortable with the idea to invest in a very volatile and fragile context: post-conflict zones. And at the same time the programme would have to present such an ambitious leap in service to the beneficiaries that governments would be more comfortable to participate in a scheme where they pay a premium only in case of success”, declared François de Borchgrave, Co-Founder and Managing Partner at KOIS Invest.

“Launching this first impact bond in the humanitarian space required great leadership and change in mind-set within the ICRC. Moving from a donor-driven model to one based on efficiency gains, forward planning and pay-for-success is a leap that will hopefully bring new sources of funding to cater to the world’s humanitarian needs”, commented Charles-Antoine Janssen, Co-Founder and Managing Partner at KOIS Invest.

The PHII balances risk protection for donor governments and rewards for the investors, while encouraging innovation for the ICRC to deliver services to people in need at an unprecedented efficiency level. If successful, every year thousands with disabilities will be supported by the centres, which are scheduled to be operational within the next three years.

KOIS Invest is a leading international impact investing organization specialized in asset management and innovative financial advisory services.
KOIS Invest’s mission is to develop solutions to key social and environmental issues that have the potential to generate lasting positive societal impact and deliver attractive financial returns.

KOIS Invest has previously structured impact bonds on employment generation for fragile communities in Europe and is currently structuring a host of impact bonds focused on themes ranging from refugee employment in the Middle East to childcare protection in Europe.

The firm is headquartered in Brussels with offices in London, Mumbai and Paris.

Learn more at https://www.koisinvest.com/

Damon van der Linde, External Relations Associate
Damon@koisinvest.com
+3225343676
Rue de Livourne 41 Livornostraat, B-1050, Brussels, Belgium

Danielle Cohen Henriquez, External Relations Manager
Danielle@koisinvest.com
+32466231380

Serena Guarnaschelli, Partner, Head of Innovative Finance
Serena@koisinvest.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release KOIS Invest designs the world’s first Humanitarian Impact Bond for the International Committee of the Red Cross here

News-ID: 713439 • Views:

More Releases for ICRC

ICRC-Weyer, Allied Clinical Management Form MEDIS Research Group
In a move to better meet requirements of clinical trial sponsors, ICRC-Weyer and Allied Clinical Management have entered into a strategic partnership by forming MEDIS Research Group. The partnership will enable the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process. The decision to form MEDIS Research Group came as a reaction to a shift in the market towards
ICRC-Weyer To Expand Pharmacovigilance Services For Mid-Sized Pharma Companies
In a move to better meet drug-safety related service requirements by small to mid-sized pharmaceutical sponsors ICRC-Weyer has expanded its services portfolio in regards to pharmacovigilance and pharmacovigilance writing. ‘Our pharmacovigilance services comprise SAE/AE reporting as well as writing Development Safety Update Reports, Periodic Safety Update Reports, Risk Management Plans and more’ says Dr Ulrike Treichel, Head of Pharmacovigilance at ICRC-Weyer. ‘Furthermore, we setup and maintain a validated safety database. We
Clinical CRO ICRC-Weyer To Boost Drug Safety Services For Investigator Trials
The Berlin-based clinical contract research organization (CRO), ICRC-Weyer GmbH, has announced it will boost its drug-safety related Pharmacovigilance Services for Investigator-Initiated Trials amid an increasing demand by trial sponsors. An increase in the number of requests by trial sponsors for regulatory-compliant drug safety reporting for investigator-initiated trials (IITs) has led the German CRO ICRC-Weyer to amend their services portfolio towards providing these services to large and mid-sized pharmaceutical trial sponsors. ‘A large
ICRC-Weyer To Enhance Pharmacovigilance Risk Management
The Berlin-based clinical contract research organization (CRO) ICRC-Weyer has made further enhancements to their Pharmacovigilance risk management. By integrating medical review procedures into the Pharmacovigilance system the company is now able to provide efficient risk management strategies in line with current market and regulatory developments. The decision to pursue this integration process was made following ICRC-Weyer’s recent participation at the Evolution Summit in Munich, Germany, an industry forum bringing together representatives
ICRC-Weyer Clinical CRO Looks Back At A Successful Year 2012
The management of ICRC-Weyer GmbH looks back at a successful year 2012, with a number of new collaborations and partnerships in the area of outsourcing clinical services. According to J. Daniel Weyer, Managing Director at ICRC-Weyer, the success results from the hard work of a devoted team combined with the company’s constant enhancements to their existing services portfolio. ‘A lot has happened this year’ says Mr Weyer. ‘We have successfully adjusted
Clinical CRO ICRC-Weyer Ready For Increase In Advanced Therapy Trials
ICRC-Weyer’s recent participation in the NanoKTN biotechnology meeting in Berlin proved to be both informative and successful. The event which took place at the British Embassy in Berlin on September 5th, 2012 was attended by two members of the ICRC-Weyer team. The meeting provided a platform for biotech companies and service providers from the UK and Germany to present their work in the field of regenerative medicine and engage in